Medical Genetics

The Biology of Sialidosis: Why the Body’s Recycling System Fails

At a Glance

Sialidosis type 1 results from NEU1 gene variants that reduce alpha-sialidase, causing sialylated molecules to accumulate in lysosomes. Enzyme activity testing and NEU1 sequencing help confirm the diagnosis and distinguish it from similar disorders.

While Sialidosis Type 1 is a single diagnosis, its roots lie in a complex biological “traffic jam” inside your cells. Understanding this mechanism—and how doctors tell it apart from other similar conditions—can help you feel more grounded in your diagnosis.

The Biological Mechanism: A Recycling Failure

Inside almost every cell in your body are small compartments called lysosomes. Think of these as your cell’s recycling centers ^[1]. Their job is to break down old proteins and sugars so the cell can reuse the parts.

In Sialidosis Type 1, a mutation in the NEU1 gene prevents your body from making enough of an enzyme called alpha-sialidase (also known as neuraminidase 1) ^[2]^[1].

The Job: This enzyme’s specific job is to “clip” a sugar molecule called sialic acid off the ends of certain proteins and fats ^[2].
The Problem: Without enough alpha-sialidase, these sialic-acid-tagged molecules (called sialylated molecules) cannot be recycled. They begin to pile up inside the lysosomes ^[2]^[1].
The Consequence: Over time, this toxic buildup causes the lysosomes to swell and eventually damages the cell. This damage is most noticeable in your nervous system and your eyes, leading to the “jerks” (myoclonus) and balance issues typical of the condition ^[3]^[4].

Type 1 vs. Type 2: Residual Activity

Doctors often discuss how much “working” enzyme you have left. This is often called residual enzyme activity ^[2]^[5].

While it is a helpful concept, the correlation between your exact variants (genotype) and your symptoms (phenotype) is imperfect. The “residual activity rule” is not perfectly absolute.

Type 1 (The Later-Onset Form): Often, one or both of the variants may leave some residual activity. This is partly why Type 1 starts later in life and generally avoids severe systemic issues ^[5]^[2].
Type 2 (The Severe Form): Often involves less residual working enzyme, which causes symptoms to start in infancy or early childhood and leads to more widespread physical changes, such as an enlarged liver or skeletal issues ^[6]^[7]^[8].

The “Cherry-Red Spot” and Other Conditions

A “cherry-red spot” is a striking visual finding where the center of your retina looks bright red compared to the surrounding pale, “cloudy” tissue ^[9]. While it is a hallmark of Sialidosis, several other rare diseases can cause it. Doctors must use enzyme and genetic tests to tell them apart:

Condition	Underlying Defect	Clues for Doctors
Sialidosis Type 1	Alpha-sialidase (NEU1)	Onset in teens; mainly neurological. ^[2]
Galactosialidosis	Cathepsin A (CTSA)	Often looks like Sialidosis but may include physical features like coarse facial skin. ^[10]
GM1 Gangliosidosis	Beta-galactosidase	Usually starts in infancy; can affect heart and bones. ^[11]
Tay-Sachs Disease	Hexosaminidase A	Mostly affects infants; rapid loss of motor skills. ^[12]
Niemann-Pick (Type C)	Lipid transport proteins	Causes lipid accumulation; can cause difficulty moving the eyes up and down. ^[13]

How the Diagnosis is Confirmed

Because symptoms can overlap with these other conditions, your doctor likely used two main tools to support a diagnosis of Sialidosis Type 1:

Enzyme Assay: Measuring the actual activity of the alpha-sialidase enzyme in your skin cells (fibroblasts) or white blood cells. In Type 1, this activity can be markedly reduced ^[14]^[15].
Genetic Testing: Sequencing the NEU1 gene to find the two specific mutations (one from each parent) that are causing the enzyme shortage ^[14]^[16].

Identifying your specific genetic variants helps confirm your diagnosis and distinguishing it from other metabolic conditions.

Common questions in this guide

What causes Sialidosis Type 1?

Sialidosis Type 1 is caused by changes in the NEU1 gene, which reduce the activity of the alpha-sialidase enzyme. Without enough of this enzyme, certain sugar-tagged molecules cannot be recycled and build up inside lysosomes, the cell’s recycling compartments.

What does residual enzyme activity mean in Sialidosis Type 1?

Residual enzyme activity is the amount of alpha-sialidase that still works. Type 1 often has some remaining activity, which may help explain its later onset and mainly neurological features, but the enzyme result alone cannot predict exactly how symptoms will develop.

How is Sialidosis Type 1 confirmed?

Doctors may measure alpha-sialidase activity in white blood cells or skin cells called fibroblasts and sequence the NEU1 gene. Finding markedly reduced enzyme activity together with two relevant NEU1 variants, one inherited from each parent, supports the diagnosis.

Is a cherry-red spot unique to Sialidosis Type 1?

No. A cherry-red spot in the retina can occur in Sialidosis, but it is also seen in several other rare metabolic diseases. Enzyme testing and genetic testing help doctors determine the underlying condition.

How does Sialidosis Type 1 differ from Type 2?

Type 1 usually begins later, often in the teen years, and is mainly neurological. Type 2 usually begins in infancy or early childhood and can cause more widespread physical findings, but the amount of remaining enzyme activity does not predict every person’s symptoms perfectly.

Get notified when new evidence is published on Sialidosis type 1.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

References (16)

1
Conventional and Unconventional Therapeutic Strategies for Sialidosis Type I.
Mosca R, van de Vlekkert D, Campos Y, et al.
Journal of clinical medicine 2020; (9(3)) doi:10.3390/jcm9030695.
PMID: 32143456
2
Type 1 sialidosis presenting with ataxia, seizures and myoclonus with no visual involvement.
Mohammad AN, Bruno KA, Hines S, Atwal PS
Molecular genetics and metabolism reports 2018; (15()):11-14 doi:10.1016/j.ymgmr.2017.12.005.
PMID: 30023283
3
Genetic and clinical characterization of mainland Chinese patients with sialidosis type 1.
Han X, Wu S, Wang M, et al.
Molecular genetics & genomic medicine 2020; (8(8)):e1316 doi:10.1002/mgg3.1316.
PMID: 32453490
4
Gene therapy corrects the neurological deficits of mice with sialidosis.
Hwu WL, Chang K, Liu YH, et al.
Gene therapy 2024; (31(5-6)):263-272 doi:10.1038/s41434-024-00443-3.
PMID: 38321198
5
Clinical and Structural Characteristics of NEU1 Variants Causing Sialidosis Type 1.
Li Y, Liu Y, Wang R, et al.
Journal of movement disorders 2024; (17(3)):282-293 doi:10.14802/jmd.23145.
PMID: 38600684
6
Ascites in infantile onset type II Sialidosis.
Tazi K, Guy-Viterbo V, Gheldof A, et al.
JIMD reports 2022; (63(4)):316-321 doi:10.1002/jmd2.12305.
PMID: 35822090
7
Identification of a homozygous deletion of the NEU1 gene in a patient with type II sialidosis presenting isolated fetal ascites and central nervous system hypoplasia.
Mitsiakos G, Gialamprinou D, Chouchou P, et al.
Hippokratia 2019; (23(4)):169-171.
PMID: 32742167
8
Severe kidney dysfunction in sialidosis mice reveals an essential role for neuraminidase 1 in reabsorption.
Kho I, Demina EP, Pan X, et al.
JCI insight 2023; (8(20)).
PMID: 37698928
9
Optical Coherence Tomography Findings in Cherry-Red Spot: Implications for Understanding Pathophysiology and Visual Prognosis.
Lee T, Velez FG, Galoyan N, et al.
Journal of pediatric ophthalmology and strabismus 2023; (60(6)):435-440 doi:10.3928/01913913-20230123-01.
PMID: 36803241
10
Galactosialidosis Type IIb with Bilateral Macular Cherry-Red Spots but Mild Dysfunction.
Fukuyo H, Inoue Y, Takahashi H, et al.
Case reports in ophthalmology 2020; (11(2)):306-314 doi:10.1159/000508066.
PMID: 32774297
11
The Clinical and Molecular Spectrum of GM1 Gangliosidosis.
Arash-Kaps L, Komlosi K, Seegräber M, et al.
The Journal of pediatrics 2019; (215()):152-157.e3 doi:10.1016/j.jpeds.2019.08.016.
PMID: 31761138
12
Tay-Sachs disease: a novel mutation from India.
Khera D, John J, Singh K, Faruq M
BMJ case reports 2018; (11(1)) doi:10.1136/bcr-2018-225916.
PMID: 30567231
13
Lysosomal Storage Disorders in Indian Children with Neuroregression Attending a Genetic Center.
Sheth J, Mistri M, Bhavsar R, et al.
Indian pediatrics 2015; (52(12)):1029-33 doi:10.1007/s13312-015-0768-x.
PMID: 26713986
14
Multigene panel next generation sequencing in a patient with cherry red macular spot: Identification of two novel mutations in NEU1 gene causing sialidosis type I associated with mild to unspecific biochemical and enzymatic findings.
Mütze U, Bürger F, Hoffmann J, et al.
Molecular genetics and metabolism reports 2017; (10()):1-4 doi:10.1016/j.ymgmr.2016.11.004.
PMID: 27942463
15
Clinical and electrophysiological characteristics of a type 1 sialidosis patient with a novel deletion mutation in NEU1 gene.
Fan SP, Lee NC, Lin CH
Journal of the Formosan Medical Association = Taiwan yi zhi 2020; (119(1 Pt 3)):406-412 doi:10.1016/j.jfma.2019.07.017.
PMID: 31371146
16
Sialidosis type 1 in a Turkish family: a case report and review of literatures.
Kılıç M, İcil S, Sezer A, et al.
Journal of pediatric endocrinology & metabolism : JPEM 2025; (38(2)):176-186 doi:10.1515/jpem-2024-0468.
PMID: 39733340

This page is for informational purposes only and does not constitute medical advice. A metabolic specialist, geneticist, neurologist, or ophthalmologist can interpret your NEU1 results, enzyme testing, and symptoms.